Detailed guidance on administration and dosage of serputinib/serpatinib

Selpercatinib is an oral small molecule RET inhibitor, used to treat RET gene fusion or mutation-positive tumors, including advanced non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other RET-related solid tumors. The dosage should be strictly in accordance with the doctor's prescription, and individualized adjustments should be made according to the patient's age, weight, organ function status and comorbid symptoms. For adults and adolescents over 12 years old and weighing ≥50kg, the recommended standard dose is 160mg twice daily; for those weighing <50kg, the recommended standard dose is 150mg twice daily. The dosage for pediatric patients needs to be adjusted based on body surface area (BSA) and combined with the recommendations of the US FDA or NCCN guidelines.

The drug must be swallowed whole and must not be crushed or chewed to ensure sustained release mechanism and pharmacokinetic stability. The drug should be taken on an empty stomach or at any time after a meal, but avoid ingesting CYP3A4 inhibitors such as grapefruit juice at the same time to prevent abnormal increase in drug plasma concentration. If the patient experiences mild adverse reactions such as hypertension, elevated transaminases, diarrhea or QT interval prolongation, the dose can be adjusted according to the toxicity level, such as reducing to 120 mg or 80 mg twice a day; in the case of severe toxicity or intolerance, the medication should be suspended and permanently discontinued if necessary.

In addition, for patients with abnormal liver and kidney function, the organ reserve function needs to be evaluated before first use. Patients with mild liver or kidney damage can usually maintain the original dose, but those with moderate or severe impairment need to adjust the dose based on individual pharmacokinetic parameters. During the medication process, liver function, electrolytes, electrocardiogram, blood pressure and other indicators need to be monitored regularly to prevent and promptly handle potential toxic reactions. To sum up, although seputinib is a new targeted drug with remarkable efficacy, its medication regimen requires strict medical supervision, and individualized management is the key to ensuring efficacy and safety.

Reference:https://en.wikipedia.org/wiki/Selpercatinib